Asprosin is a novel peptide hormone produced and secreted by white adipose tissues. Asprosin associated with insulin resistance and promotes hepatic glucose production. Previous studies showed that serum asprosin was raised in the general population with polycystic ovary syndrome (PCOS). However, there were studies supporting the opposite. Also, there were studies that showed the highest levels of asprosin was due to insulin resistance, as well as in type 2 diabetes patients. PCOS is one of the metabolic disorders related to insulin resistance. Therefore, the current study aims to evaluate the levels of asprosin in the blood serum of women with PCOS compared to the healthy women who resident in Duhok in the Kurdistan Region of Iraq. A cross-sectional study was conducted from 20th of June, 2020 to 11th of January, 2021 at Obstetrics and Gynecology Hospital and Mazi medical clinics. Serum asprosin level was determined in 75 women with PCOS (18-44 years) and 96 healthy women. SPSS software was utilized for analyzing the study data. The (means ± SD) of demographic parameters (body mass index (BMI) and waist circumference (WC)) in women with PCOS were significantly highest in comparison to healthy women. The biochemical parameters (serum asprosin, fasting blood sugar (FBS), fasting insulin (FI), total cholesterol (TC), and triglyceride (TG)) in women with PCOS also were remarkably higher compared to healthy women with the exception of high-density lipoprotein- cholesterol (HDL-C). The current data show that serum asprosin variance significantly between WC, BMI, FBS, FI, TC, TG and HDL-C. The study confirms that serum asprosin in women with PCOS was higher than in the healthy women. In addition in women with PCOS it was found that serum asprosin was positively correlated with BMI, WC, FBS, FI, HOMA-IR, TC and TG (P<0.05). Except, HDL-C was negatively correlated with serum asprosin (P<0.01).
Alan, M., Gurlek, B., Yilmaz, A., Aksit, M., Aslanipour, B., Gulhan, I. Mehmet, C., et al. (2019). Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology,35(3):220-223.
Amiri, M., Tehrani, F.R., Behboudi-Gandevani, S., Bidhendi-Yarandi, R. and Carmina, E. (2020). Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reproductive Biology and Endocrinology, 18(1):23.
Chang, C.L., Huang, S.Y., Hsu, Y.C., Chin, T.H., Soong, Y.K. (2019). The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Scientific Reports, 9(1):6447.
Coelho, M., Oliveira, T., Fernandes, R. (2013). Biochemistry of adipose tissue: an endocrine organ. Archives of Medical Science, 9(2):191-200.
Deniz, R., Yavuzkir, S., Ugur, K., Ustebay, D.U., Baykus, Y., Ustebay, S. Aydin, S. (2020). Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. Journal of Obstetrics and Gynaecology,41(2):279-284.
Deore, D.N., Surwase, S.P., Masroor, S., Khan, S.T., Kathore, V. (2012). A Cross Sectional Study on the Relationship Between the Body Mass Index (BMI) and the Audiovisual Reaction Time (ART). Journal of Clinical And Diagnostic Research;6(9):1466-8.
Duerrschmid, C., He, Y., Wang, C., Li, C., Bournat, J.C., Romere, C. Saha, P.K., et al. (2017). Asprosin is a centrally acting orexigenic hormone. Nature Medicine, 23(12):1444-1453.
Dumesic, D.A., Oberfield, S.E., Stener-Victorin, E., Marshall, J.C., Laven, J.S., Legro, R.S. (2015). Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocrine Reviews, 36(5):487-525.
Escobar-Morreale, H.F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology,14(5):270-284.
Ghaffarzad, A., Amani, R., Sadaghiani, M., Darabi, M., Cheraghian, B. (2016). Correlation of Serum Lipoprotein Ratios with Insulin Resistance in Infertile Women with Polycystic Ovarian Syndrome: A Case Control Study. International Journal Of Fertility & Sterility, 10(1):29-35.
Jiang, Y., Liu, Y., Yu, Z., Yang, P., Xie, L., Shang, X. Zhao, S. (2020). Serum asprosin level in different subtypes of polycystic ovary syndrome: a cross-sectional study, PREPRINT (Version 1) available at Research Square.
Legro, R.S. (2012). Obesity and PCOS: implications for diagnosis and treatment. Seminars in reproductive medicine, 30(6):496-506.
Li, X., Liao, M., Shen, R., Zhang, L., Hu, H., Wu, J. Wang, X., et al. (2018). Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases. Mediators of Inflammation,2018:7375294.
Lim, S.S., Norman, R.J., Davies, M.J., Moran, L.J. (2013). The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obesity Reviews,14(2):95-109.
Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia,28(7):412-419.
Ozkan, S., Yilmaz, O.C., Yavuz, B. (2020). Increased masked hypertension prevalence in patients with polycystic ovary syndrome (PCOS). Clinical and Experimental Hypertension, 42(8):681-684.
Pergialiotis, V., Trakakis, E., Chrelias, C., Papantoniou, N., Hatziagelaki, E. (2018). The impact of mild hypercholesterolemia on glycemic and hormonal profiles, menstrual characteristics and the ovarian morphology of women with polycystic ovarian syndrome. Hormone Molecular Biology And Clinical Investigation,34(3). 20180002.
Polak, K., Czyzyk, A., Simoncini, T., Meczekalski, B. (2017). New markers of insulin resistance in polycystic ovary syndrome. Journal of Endocrinological Investigation,40(1):1-8.
Rojas, J., Chavez, M., Olivar, L., Rojas, M., Morillo, J., Mejias, J. Calvo, M., Bermudez, V. (2014). Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. International Journal of Reproductive Medicine,2014:719050.
Romere, C., Duerrschmid, C., Bournat, J., Constable, P., Jain, M., Xia, F., Saha, P.K., et al. (2016). Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell, 165(3):566-579.
Rosenfield, R.L., Ehrmann, D.A. (2016). The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 37(5):467-520.
The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19, 41-47.
Tsouma, I., Kouskouni, E., Demeridou, S., Boutsikou, M., Hassiakos, D., Chasiakou, A. Hassiakou, S., et al. (2014). Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: influence of adipocytokines levels. In vivo, 28(5):935-939.
Ugur, K., Aydin, S. (2019). Saliva and Blood Asprosin Hormone Concentration Associated with Obesity. International journal of endocrinology,2019:2521096.
Wang, Y., Qu, H., Xiong, X., Qiu, Y., Liao, Y., Chen, Y., Zheng, Y., et al. (2018). Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion. Mediators of Inflammation, 2018:9471583.
Witchel, S.F., Oberfield, S.E., Peña, (2019). Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. Journal of the Endocrine Society, 3(8):1545-1573.
Yuan, M., Li, W., Zhu, Y., Yu, B., Wu, J. (2020). Asprosin: A Novel Player in Metabolic Diseases. Frontiers in Endocrinology, 11:64.
Zhang, L., Chen, C., Zhou, N., Fu, Y., Cheng, X. (2019). Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clinica Chimica act,489:183-188.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2021 Array